Muscle / Performance · Research guide

IGF-1 DES peptide: Muscle / Performance research guide

Catalogue reference · Laboratory research only

Not medical advice. IGF-1 DES is sold for research. This guide does not recommend dosing, diagnosis, or therapy.

IGF-1 DES is listed in our catalogue under “Muscle / Performance.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

Des(1-3)IGF-1 truncated 67-amino-acid IGF-1 analogue retains full IGF-1R affinity (Kd ~0.5 nM) with only 1% IGFBP binding, conferring ~10-fold enhanced bioactivity.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.

Typical study contexts & reported directions

Muscle injury, overload, or culture models examining growth-factor cascades and repair timelines.
IGF/IGFBP biology in cell lines and animals where the question is signalling, not “gains” in people.
Peer-reviewed preclinical work sometimes describes experiments that track whether retains full IGF-1R binding affinity (Kd ~0.5 nM) with only ~1% IGFBP interaction — ~10× greater bioactivity than native IGF-1
Peer-reviewed preclinical work sometimes describes experiments that track whether absence of Glu3 virtually eliminates sequestration by all six IGFBPs, maximizing free-peptide bioavailability
Peer-reviewed preclinical work sometimes describes experiments that track whether activates PI3K-Akt-mTOR axis for ribosomal biogenesis and translational regulation of protein synthesis
Peer-reviewed preclinical work sometimes describes experiments that track whether mAPK/ERK cascade activation drives cellular proliferation and differentiation in myogenic tissue

Why Muscle / Performance research discusses this compound

Here the literature centres on muscle repair, growth-factor signalling, and how tissues respond after overload or injury in preclinical work.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

Retains full IGF-1R binding affinity (Kd ~0.5 nM) with only ~1% IGFBP interaction — ~10× greater bioactivity than native IGF-1
Absence of Glu3 virtually eliminates sequestration by all six IGFBPs, maximizing free-peptide bioavailability
Activates PI3K-Akt-mTOR axis for ribosomal biogenesis and translational regulation of protein synthesis
MAPK/ERK cascade activation drives cellular proliferation and differentiation in myogenic tissue
Selective anabolic effects particularly pronounced in gut tissue regeneration in vivo
Naturally occurring post-translational cleavage product found in brain, colostrum, and uterine tissue

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 50-100 μg subcutaneously or intramuscularly · Pre- or post-training, typically bilaterally into target muscle groups · MW 7368.5 Da (67 aa) vs full-length IGF-1 MW 7649 Da (70 aa). Three disulfide bonds (Cys6-Cys48, Cys18-Cys61, Cys47-Cys52) maintain tertiary structure. Very short half-life (~20-30 min) due to lack of IGFBP protection. Produced recombinantly in E. coli (non-glycosylated). Site-specific injection maximizes local autocrine/paracrine signaling.

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

What is IGF-1 DES in plain language?
IGF-1 DES is a research peptide we catalogue under “Muscle / Performance.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Does this page give medical advice or dosing instructions for IGF-1 DES?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Where can I see purity, variants, and pricing for IGF-1 DES?
Use the “View product” button to open the canonical shop listing for IGF-1 DES, where specifications and research SKU details are shown.

What about online case reports, before-and-after stories, or forum “logs” for IGF-1 DES?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Need vial specs & pricing?

Open the shop listing for variants, purity notes, and research SKU details.

View product

Also known as: IGF-1 DES, Des(1-3)IGF-1, Truncated IGF-1, IGF-1 Des(1-3), Des-IGF-1, IGF-1 Analog, Des-N-Terminal IGF-1